Declining breast cancer incidence and decreased HRT use

The Lancet

Volumn 373, Issue 9662, 2009, Pages 459-460

  Brewster, David H ^a,b   Sharpe, Katharine H ^a   Clark, Douglas I ^a   Collins, Joanne ^a  

^a INFORMATION SERVICES DIVISION   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; RALOXIFENE;

AGE DISTRIBUTION; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SCREENING; DEVELOPED COUNTRY; DISEASE COURSE; DRUG EFFECT; DRUG USE; GROUPS BY AGE; HEALTH PROGRAM; HORMONE SUBSTITUTION; HUMAN; LETTER; MAMMOGRAPHY; NORWAY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; UNITED KINGDOM;

EID: 59349088377     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60165-3     Document Type: Letter

References (5)

1. Kumle M. Declining breast cancer incidence and decreased HRT use. Lancet 372 (2008) 608-610
2. Anon. Scottish breast screening programme 2006 follow-up (2006), NHS Quality Improvement Scotland, Edinburgh
3. Anon. British national formulary 55 (2008), BMJ Publishing Group and RPS Publishing, London
4. Olevsky O.M., and Martino S. Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women. Menopause 15 suppl 4 (2008) 790-796
5. Information Services Division Scotland. Breast screening. http://www.isdscotland.org/isd/cancer-breast-screening.jsp?pContentID=16 22&p_applic=CCC&p_service=Content.show& (accessed Aug 26, 2008).